This article is more than 5 years old. Information may no longer be current.

ai4gi leads advance of GI artificial intelligence tools in new partnership

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, Healio Gastroenterology and Liver Disease spoke with Douglas K. Rex, MD, a gastroenterologist from Indiana University and advisory board chairman at ai4gi, regarding the codevelopment agreement between ai4gi and Olympus.

“These two companies coming together are going to create an opportunity that is going to be fantastic for endoscopy and for endoscopists,” Rex said. “I am very confident that they’re going to be able to develop some tools that are going to be tremendous to improve clinical decision-making during colonoscopies.”

To hear more about ai4gi, watch the video with company founder Michael Byrne, MD. To find out more about the partnership with Olympus, watch the video with group vice president Kurt Heine.

Disclosure: Rex reports he received consulting fees, grant or research support, or other financial benefits from Aries Pharmaceutical, Boston Scientific, Braintree, Colonary Solutions, Covidien/Medtronic, EndoAid Ltd, Olympus, Paion, and Sebela.